Si-bone Inc (SIBN)

$15.08

-0.19

(-1.24%)▲

Market is closed - opens 7 PM, 25 Apr 2024

Insights on Si-bone Inc

  • Increasing Revenue

    Revenue is up for the last 8 quarters, 22.43M → 38.85M (in $), with an average increase of 7.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -10.02M → -10.98M (in $), with an average decrease of 9.6% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 42.7% return, outperforming this stock by 73.7%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 70.6% return, outperforming this stock by 128.0%

Performance

  • $14.86
    $15.27
    $15.08
    downward going graph

    1.46%

    Downside

    Day's Volatility :2.69%

    Upside

    1.24%

    downward going graph
  • $14.84
    $29.51
    $15.08
    downward going graph

    1.59%

    Downside

    52 Weeks Volatility :49.71%

    Upside

    48.9%

    downward going graph

Returns

PeriodSi-bone IncSector (Health Care)Index (Russel 2000)
3 Months
-24.64%
1.7%
0.0%
6 Months
-8.94%
11.3%
0.0%
1 Year
-30.98%
5.4%
1.3%
3 Years
-56.85%
13.9%
-22.1%

Highlights

Market Capitalization
627.1M
Book Value
$4.16
Earnings Per Share (EPS)
-1.13
Wall Street Target Price
26.22
Profit Margin
-31.2%
Operating Margin TTM
-32.18%
Return On Assets TTM
-15.12%
Return On Equity TTM
-32.38%
Revenue TTM
138.9M
Revenue Per Share TTM
3.61
Quarterly Revenue Growth YOY
21.6%
Gross Profit TTM
90.7M
EBITDA
-41.5M
Diluted Eps TTM
-1.13
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.99
EPS Estimate Next Year
-0.76
EPS Estimate Current Quarter
-0.28
EPS Estimate Next Quarter
-0.26

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Si-bone Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
13
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 73.87%

Current $15.08
Target $26.22

Company Financials

FY18Y/Y Change
Revenue
55.4M
↑ 15.42%
Net Income
-17.5M
↓ 24.25%
Net Profit Margin
-31.51%
↑ 16.5%
FY19Y/Y Change
Revenue
67.3M
↑ 21.53%
Net Income
-42.6M
↑ 143.95%
Net Profit Margin
-63.26%
↓ 31.75%
FY20Y/Y Change
Revenue
73.4M
↑ 9.04%
Net Income
-48.5M
↑ 14.01%
Net Profit Margin
-66.15%
↓ 2.89%
FY21Y/Y Change
Revenue
90.2M
↑ 22.84%
Net Income
-60.1M
↑ 23.87%
Net Profit Margin
-66.7%
↓ 0.55%
FY22Y/Y Change
Revenue
106.4M
↑ 18.03%
Net Income
-62.9M
↑ 4.62%
Net Profit Margin
-59.11%
↑ 7.59%
FY23Y/Y Change
Revenue
138.9M
↑ 30.52%
Net Income
-43.3M
↓ 31.11%
Net Profit Margin
-31.2%
↑ 27.91%
Q3 FY22Q/Q Change
Revenue
26.4M
↑ 3.31%
Net Income
-14.8M
↓ 22.96%
Net Profit Margin
-55.8%
↑ 19.03%
Q4 FY22Q/Q Change
Revenue
32.0M
↑ 20.89%
Net Income
-11.1M
↓ 25.04%
Net Profit Margin
-34.6%
↑ 21.2%
Q1 FY23Q/Q Change
Revenue
32.7M
↑ 2.36%
Net Income
-10.1M
↓ 8.48%
Net Profit Margin
-30.94%
↑ 3.66%
Q2 FY23Q/Q Change
Revenue
33.3M
↑ 1.83%
Net Income
-11.2M
↑ 10.74%
Net Profit Margin
-33.65%
↓ 2.71%
Q3 FY23Q/Q Change
Revenue
34.0M
↑ 2.13%
Net Income
-10.0M
↓ 10.57%
Net Profit Margin
-29.46%
↑ 4.19%
Q4 FY23Q/Q Change
Revenue
38.9M
↑ 14.24%
Net Income
-11.0M
↑ 9.59%
Net Profit Margin
-28.26%
↑ 1.2%
FY18Y/Y Change
Total Assets
138.5M
↑ 286.56%
Total Liabilities
48.3M
↓ 70.75%
FY19Y/Y Change
Total Assets
117.0M
↓ 15.53%
Total Liabilities
54.0M
↑ 11.74%
FY20Y/Y Change
Total Assets
223.1M
↑ 90.7%
Total Liabilities
53.8M
↓ 0.41%
FY21Y/Y Change
Total Assets
190.5M
↓ 14.63%
Total Liabilities
56.1M
↑ 4.29%
FY22Y/Y Change
Total Assets
157.6M
↓ 17.3%
Total Liabilities
59.3M
↑ 5.64%
FY23Y/Y Change
Total Assets
230.4M
↑ 46.25%
Total Liabilities
61.1M
↑ 3.04%
Q3 FY22Q/Q Change
Total Assets
158.3M
↓ 4.74%
Total Liabilities
55.4M
↓ 11.01%
Q4 FY22Q/Q Change
Total Assets
157.6M
↓ 0.45%
Total Liabilities
59.3M
↑ 6.88%
Q1 FY23Q/Q Change
Total Assets
149.1M
↓ 5.38%
Total Liabilities
55.1M
↓ 6.98%
Q2 FY23Q/Q Change
Total Assets
233.8M
↑ 56.85%
Total Liabilities
56.4M
↑ 2.36%
Q3 FY23Q/Q Change
Total Assets
230.9M
↓ 1.26%
Total Liabilities
57.3M
↑ 1.52%
Q4 FY23Q/Q Change
Total Assets
230.4M
↓ 0.2%
Total Liabilities
61.1M
↑ 6.59%
FY18Y/Y Change
Operating Cash Flow
-14.5M
↓ 17.18%
Investing Cash Flow
-97.8M
↑ 20365.48%
Financing Cash Flow
115.2M
↑ 795.27%
FY19Y/Y Change
Operating Cash Flow
-31.6M
↑ 117.83%
Investing Cash Flow
13.5M
↓ 113.79%
Financing Cash Flow
3.5M
↓ 96.97%
FY20Y/Y Change
Operating Cash Flow
-30.7M
↓ 3.05%
Investing Cash Flow
-62.9M
↓ 566.36%
Financing Cash Flow
136.4M
↑ 3810.58%
FY21Y/Y Change
Operating Cash Flow
-39.5M
↑ 28.93%
Investing Cash Flow
51.6M
↓ 181.98%
Financing Cash Flow
-1.7M
↓ 101.25%
FY22Y/Y Change
Operating Cash Flow
-41.7M
↑ 5.37%
Investing Cash Flow
-2.8M
↓ 105.46%
Financing Cash Flow
2.2M
↓ 228.4%
Q3 FY22Q/Q Change
Operating Cash Flow
-6.5M
↓ 56.02%
Investing Cash Flow
8.7M
↓ 20.5%
Financing Cash Flow
106.0K
↓ 91.38%
Q4 FY22Q/Q Change
Operating Cash Flow
-6.8M
↑ 3.8%
Investing Cash Flow
89.0K
↓ 98.98%
Financing Cash Flow
693.0K
↑ 553.77%
Q1 FY23Q/Q Change
Operating Cash Flow
-10.8M
↑ 58.72%
Investing Cash Flow
11.7M
↑ 13049.44%
Financing Cash Flow
1.2M
↑ 73.88%
Q2 FY23Q/Q Change
Operating Cash Flow
-3.6M
↓ 66.61%
Investing Cash Flow
2.3M
↓ 80.51%
Financing Cash Flow
89.1M
↑ 7296.1%

Technicals Summary

Sell

Neutral

Buy

Si-bone Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Si-bone Inc
Si-bone Inc
-0.46%
-8.94%
-30.98%
-56.85%
-8.05%
Stryker Corporation
Stryker Corporation
-4.04%
30.03%
12.47%
26.98%
79.97%
Dexcom, Inc.
Dexcom, Inc.
-1.59%
63.45%
11.22%
31.69%
366.88%
Boston Scientific Corp.
Boston Scientific Corp.
8.35%
45.85%
42.65%
72.49%
97.43%
Abbott Laboratories
Abbott Laboratories
-2.84%
14.24%
-2.8%
-12.8%
36.85%
Medtronic Plc
Medtronic Plc
-3.44%
12.58%
-10.38%
-38.23%
-7.46%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Si-bone Inc
Si-bone Inc
NA
NA
NA
-0.99
-0.32
-0.15
NA
4.16
Stryker Corporation
Stryker Corporation
40.64
40.64
2.92
11.85
0.18
0.07
0.01
48.92
Dexcom, Inc.
Dexcom, Inc.
102.89
102.89
2.53
1.76
0.26
0.06
NA
5.37
Boston Scientific Corp.
Boston Scientific Corp.
64.48
64.48
1.8
2.25
0.09
0.04
NA
13.16
Abbott Laboratories
Abbott Laboratories
33.52
33.52
5.99
4.31
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.81
25.81
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Si-bone Inc
Si-bone Inc
Buy
$627.1M
-8.05%
NA
-31.2%
Stryker Corporation
Stryker Corporation
Buy
$127.4B
79.97%
40.64
15.44%
Dexcom, Inc.
Dexcom, Inc.
Buy
$54.6B
366.88%
102.89
14.95%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$101.4B
97.43%
64.48
11.18%
Abbott Laboratories
Abbott Laboratories
Buy
$186.7B
36.85%
33.52
13.96%
Medtronic Plc
Medtronic Plc
Buy
$107.9B
-7.46%
25.81
13.0%

Institutional Holdings

  • Brown Advisory Holdings Inc

    10.25%

  • BlackRock Inc

    9.51%

  • First Light Asset Management, LLC

    6.20%

  • Vanguard Group Inc

    5.89%

  • Orbimed Advisors, LLC

    5.58%

  • Next Century Growth Investors LLC

    3.41%

Corporate Announcements

  • Si-bone Inc Earnings

    Si-bone Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

si-bone® is focused on helping patients in one of the most under-served, under-diagnosed, and under-treated areas in orthopedics, the sacroiliac (si) joint. si-bone developed an innovative, patented implant to fuse the si joint. the ifuse implant system® provides a less invasive alternative to traditional sacroiliac (si) joint fusion surgery and has been used in over 25,000 procedures to date. the company is managed by an experienced team of executives from kyphon, medtronic, inbone, saint francis and several start up orthopedic and spine companies. the ifuse implant system is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. this includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. there are potential risks associated with the ifuse implant system. it may not be appropriate for al

Organization
Si-bone Inc
Employees
344
CEO
Ms. Laura A. Francis MBA
Industry
Health Technology

Discover More

FAQs